ArticlePharmacy (Basel, Switzerland)2025
Assessing Prescribing Patterns of Nonstatins as Add-on Therapy for Secondary Prevention in a Federally Qualified Health Center.
Article in Pharmacy (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLipid management is a key aspect of secondary atherosclerotic cardiovascular disease (ASCVD) prevention. However, real-world studies show that ~72-88% of patients with ASCVD fail to meet their low-density lipoprotein cholesterol (LDL-C) target. Nonstatin agents are available as add-on therapies that can be utilized when maximally tolerated statins are insufficient to achieve LDL-C goals. This retrospective study aimed to evaluate the current prescribing habits of nonstatins as add-on therapy to statins for secondary ASCVD prevention at a federally qualified health center (FQHC).
methodsPatients were included if they had a history of clinical ASCVD, ≥1 lipid panel obtained during the study period, and were prescribed any intensity statin.
resultsAmong 398 included participants, 11.1% were prescribed nonstatin therapy and 35.9% were meeting a LDL-C target of <70 mg/dL. There was a significant association between being prescribed ezetimibe based on the type of healthcare coverage (
conclusionsOverall, nonstatins were found to be underutilized for LDL-C management in this underserved population. Future initiatives should target ways to optimize nonstatin therapy to optimize secondary ASCVD prevention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.